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Abstract
Background: Differential use of endocrine therapy (ET) by race may contribute to breast cancer outcome disparities, but racial
differences in ET behaviors are poorly understood.
Methods: Women aged 20–74 years with a first primary, stage I–III, hormone receptor–positive (HRþ) breast cancer were in-
cluded. At 2 years postdiagnosis, we assessed nonadherence, defined as not taking ET every day or missing more than two
pills in the past 14 days, discontinuation, and a composite measure of underuse, defined as either missing pills or discontinu-
ing completely. Using logistic regression, we evaluated the relationship between race and nonadherence, discontinuation,
and overall underuse in unadjusted, clinically adjusted, and socioeconomically adjusted models.
Results: A total of 1280 women were included; 43.2% self-identified as black. Compared to white women, black women more
often reported nonadherence (13.7% vs 5.2%) but not discontinuation (10.0% vs 10.7%). Black women also more often reported
the following: hot flashes, night sweats, breast sensitivity, and joint pain; believing that their recurrence risk would not
change if they stopped ET; forgetting to take ET; and cost-related barriers. In multivariable analysis, black race remained sta-
tistically significantly associated with nonadherence after adjusting for clinical characteristics (adjusted odds ratio ¼ 2.72,
95% confidence interval ¼ 1.75 to 4.24) and after adding socioeconomic to clinical characteristics (adjusted odds ratio ¼ 2.44,
95% confidence interval ¼ 1.50 to 3.97) but was not independently associated with discontinuation after adjustment. Low re-
currence risk perception and lack of a shared decision making were strongly predictive of ET underuse across races.
Conclusions: Our results highlight important racial differences in ET-adherence behaviors, perceptions of benefits/harms,
and shared decision making that may be targeted with culturally tailored interventions.
Nationally, breast cancer mortality is 41.5% higher among black
women compared with white women, despite a historically
lower incidence rate (1). Racial differences in screening, stage at
diagnosis, insurance status, and tumor biology explain some,
but not all, of this disparity (2,3). Although breast cancer in
black women is characterized by higher estrogen receptor nega-
tivity, higher grade, and histological differences (4–10), studies
suggest that black women have worse prognoses regardless of
subtype and biologic profile of disease (11,12). In fact, the largest
racial disparity in outcomes occurs within the biologically
similar hormone receptor–positive (HRþ), HER-2-negative sub-
types, suggesting that treatment differences and other nonbio-
logical factors may explain these racial differences (11).
Failure to receive appropriate treatment (13–16) is an impor-
tant cause of observed racial disparities in breast cancer mortal-
ity (17,18). Black women are less likely to receive timely and
guideline-recommended surgery, radiation, and endocrine
therapy (ET) (19). Importantly, however, black and white women
with clinically similar disease profiles can achieve similar out-
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Oral adjuvant ET is an important part of treatment for HRþ
cancer, the majority of all breast cancer cases. Evidence sug-
gests that taking ET for up to 10 years reduces the risk of recur-
rence and cancer-specific mortality (22,23). However,
between 15% and 49% of women with HRþ disease never initi-
ate ET (24–27), and more than half do not take ET as recom-
mended (28,29), with black women having lower medication
usage (including taking medication as prescribed [adherence]
and continuing to take medication at all [continuation])
(30). Reasons for nonadherence and discontinuation may
differ by race. Beliefs about medication efficacy, patient–
provider relationship, and level of social support have all been
associated with ET underuse, but it is unknown if modifiable
factors such as these are experienced differently by black and
white women or whether correlates of nonadherence and dis-
continuation differ (31).
The social-contextual framework considers the ways in which
both health and health behaviors are influenced by one’s social
context, including access to care, material hardship, and social
support (32). It is essential to understand the complex social con-
textual predictors of ET nonadherence and discontinuation if we
are to develop culturally sensitive interventions to reduce dispar-
ities in breast cancer outcomes. Existing literature provides snap-
shots of reasons for ET underuse, but fails to elucidate racial
differences in associations (27,33,34). We sought to extend this lit-
erature by examining to what extent ET-related side effects, per-
ceptions of recurrence risk, and shared decision making explain
black/white differences in nonadherence and discontinuation.
Our analysis from a large, minority-enriched, longitudinal cohort
study provides novel insights into ET adherence behavior by race
and points to potential reasons why black women with HRþ dis-
ease may experience higher mortality.
Methods
Data
The Carolina Breast Cancer Study phase III (CBCS-III) data are
unusually rich, spanning a state with substantial racial diversity
and including patients from a wide range of economic strata, in-
surance providers, and care settings, allowing broad generaliz-
ability of findings. Notably, CBCS oversampled black women
and women younger than age 50 years, with approximately half
of participants in each of these categories, allowing inferences
about racial and age-related differences with adequate statisti-
cal power.
CBCS-III recruited women between 2008 and 2013 through rapid
case ascertainment in collaboration with the NC Central Cancer
Registry. Those who provided written informed consent
completed a baseline questionnaire regarding sociodemographics,
insurance, access to care, health behaviors, and health-related
quality of life. Patients’ medical records and tumor and blood sam-
ples also were obtained. Tumor characteristics (eg, stage,
grade, HRþ status) were ascertained from pathology laboratory
reports. Additional patient-reported data were collected via tele-
phone and mailed questionnaire at approximately
2 years postdiagnosis, with ongoing follow-up planned through
10 years postdiagnosis, and updated medical records obtained at
multiple time points. Incentives of $75 were offered for completion
of the initial baseline data collection and $10 for completion of
each of the follow-up surveys.
As part of the 2-year follow-up questionnaire, we collected
health-related quality of life data and ET-related symptom data
using the Functional Assessment of Cancer Therapy for
Breast Cancer (FACT-B) and FACT-Breast-Endocrine
Symptoms (FACT-B-ES) scales, respectively. In addition, we de-
veloped a medication usage questionnaire to understand both ex-
tent of ET use and reason-specific underuse, based upon reviews
of the literature (35–38) and input from clinical and health behav-
ior experts. This questionnaire includes a multi-item measure of
self-reported ET usage behavior as well as questions about recur-
rence risk perception, shared decision making, and overall as-
sessment of ET (Table 1). After initial development, we pretested
the questionnaire with a clinic-based sample of breast cancer
patients, conducted cognitive interviews, and refined the ques-
tionnaire based upon response patterns and feedback regarding
usability and content. This study was approved by the University
of North Carolina at Chapel Hill Institutional Review Board.
Inclusion Criteria
The parent study recruited women aged 20–74 years who
were diagnosed with a first primary invasive breast cancer be-
tween May 2008 and July 2013 and who resided in one
of 44 study counties. A total of 2328 women in the CBCS-III co-
hort were sent a 2-year follow-up survey containing ET-related
questions, which 2015 completed (87%) (Supplementary Figure
1, available online).
Among follow-up survey respondents, 1392 reported initiat-
ing or being recommended to take ET. We excluded women
who reported race other than black or white (n¼ 41), had stage
IV disease (n¼ 35), did not receive cancer-directed surgery
(n¼ 4), and experienced recurrence prior to the 2-year follow-up
survey (n¼ 32).
Primary Outcome Measure
Nonadherence was defined based on responses to two survey
items: 1) a respondent reported not taking ET as prescribed and
2) a respondent reported missing more than two pills in the
past two weeks (Figure 1). These items correlated but did not
completely overlap (r¼ .71); therefore, indication of non-
adherence from either item was combined to create a more sen-
sitive measure. Sensitivity analyses using each single-item
adherence measure were not substantively different.
Discontinuation was defined by self-report as stopping ET
completely. We also created a composite endpoint of underuse,
including both nonadherence and discontinuation behaviors,
where underuse reflects lower than 80% adherence, because all
levels of adherence below this threshold have been linked to
decrements in survival (28,39).
Primary Exposure Measure
Race was defined by a self-reported indicator of black or
white status at baseline questionnaire. In a separate question,
12 white women and 2 black women identified as Hispanic.
Because of small numbers, we did not control for Hispanic eth-
nicity in our analysis.
Covariates/Other Variables
We examined factors expected to influence a person’s motiva-
tion and self-efficacy to take ET as prescribed, using a model de-
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were measured using the validated FACT-B-ES scale (41).
Perceived risk of recurrence, difficulty of the treatment regimen,
extent of shared decision making about ET, balance of
benefits/harms, and reasons for nonadherence, including
cost-related nonadherence, were captured using our
patient-reported questionnaire (Table 1). Other covariates






Total 1033 (80.7%) 247 (19.3%) —
Race
White 611 (84.0) 116 (16.0) <.001
Black 422 (76.3) 131 (23.7)
Age at diagnosis, y
<45 214 (74.0) 75 (26.0) .003
45–54 339 (80.3) 83 (19.7)
55–64 273 (83.2) 55 (16.8)
>65 207 (85.9) 34 (14.1)
AJCC stage at diagnosis
Stage I 512 (80.4) 125 (19.6) .35
Stage II 367 (79.4) 95 (20.6)
Stage III 134 (84.3) 25 (15.7)
Unknown 20 (90.9) 2 (9.1)
Insurance status at diagnosis
Any private 824 (82.7) 172 (17.3) <.001
Medicare 85 (78.7) 23 (21.3)
Medicaid 72 (67.3) 35 (32.7)
Uninsured 51 (78.5) 14 (21.5)
Annual Income
<$15 000 129 (75.0) 43 (25.0) .03
$15 000 to <$30 000 171 (80.3) 42 (19.7)
$30 000 to $50 000 181 (77.0) 54 (23.0)
>$50 000 509 (84.1) 96 (15.9)
Did not report 43 (78.2) 12 (21.8)
Education
Did not complete high school 68 (76.4) 21 (23.6) .16
High school/some college 507 (79.3) 132 (20.7)
College/professional degree 458 (83.0) 94 (17.0)
History of receiving Herceptin
Yes 126 (77.3) 37 (22.7) .24
No 907 (81.2) 210 (18.8)
Medication type
Tamoxifen 417 (79.0) 111 (21.0) <.001
Aromatase inhibitor 615 (84.5) 113 (15.5)
Unknown 1 (4.2) 23 (95.8)
Changed ET type
Changed one or more times 253 (77.4) 74 (22.6) .008
Did not change medications 779 (83.9) 150 (16.1)
Previously received chemotherapy
Yes 556 (80.4) 111 (19.6) .73
No 447 (81.1) 136 (18.9)
Previously received radiation therapy
Yes 749 (80.8) 178 (19.2) .88
No 284 (80.4) 69 (19.6)
Surgery Type
Breast conserving 523 (81.5) 119 (18.5) .49
Mastectomy 510 (79.9) 128 (20.1)
How ET decision was made
Primarily patient decision 172 (72.9) 64 (27.1) <.001
Primarily provider decision 224 (78.6) 61 (21.4)
Patient and provider (shared) decision 555 (85.0) 98 (15.0)
No discussion: ET was just prescribed 66 (75.0) 22 (25.0)
Did not report 16 (88.9) 2 (11.1)
*Underuse is defined as self-reporting either nonadherence (not taking medication as prescribed) or discontinuation (stopping medication altogether) at 2 years post-
diagnosis. AJCC ¼ American Joint Committee on Cancer; ET ¼ endocrine therapy.
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included cancer stage at diagnosis and treatments received
(from medical records), health insurance coverage, age, educa-
tion, marital/cohabitating status, and household income.
Although we had access to some information about meno-
pausal status, it was highly correlated with age. Because we
conceptualize age as related also to unmeasured comorbidity,
medication use, and beliefs about risk/benefit trade-offs, we
opted to include age rather than menopause in our models.
Multiple specifications of age resulted in similar findings.
Analysis of variance inflation factors (VIF) was performed on fi-
nal covariates to confirm acceptably low multicollinearity
(VIF< 10).
Statistical Analysis
We first examined bivariable predictors of ET underuse. We
then used multivariable logistic regression to assess the role of
clinical factors, including age, stage, treatments, and endocrine
symptoms as well as individual mediating factors (risk percep-
tion) and social mediating factors (shared decision making), in
contributing to ET underuse. In the primary model, we consid-
ered race as a social construct without controlling separately for
socioeconomic status, as suggested by the Institute of Medicine
(42). As a secondary analysis, we added social-contextual varia-
bles (marital status, income, education, insurance status) to as-
sess the role of these factors in a model estimating the residual
direct effect of race (42).
These models assume the relationships between indepen-
dent and dependent variables are the same for black and white
women and thus report average effects across races. To assess
possible effect modification of the relationship between predic-
tors and underuse, we ran models stratified by race and con-
ducted Oaxaca-Blinder decomposition, an increasingly common
approach for evaluating disparities (43,44). This method
quantifies the proportion of variation caused by characteristic
differences (eg, black women are younger, etc.) vs those caused
Many women who have had breast cancer take endocrine therapy pills, also known as hormonal therapy or an-estrogen 
therapy, to help keep breast cancer from coming back. Specific names of these drugs are Tamoxifen, Femara (or Letrozole), 
Aromasin (or Exemestane), and Arimidex (or Anastrozole). 
1. Has your doctor ever prescribed hormonal therapy pills for you to help keep your breast cancer from coming back? 
Yes 
No
2. At this me, are you taking hormonal therapy pills?
Yes, as prescribed       
Yes, but not every day         
No, I stopped taking them
3. Over the past two weeks, how many days did you miss your hormonal therapy pills?
0, 1, 2, 3, 4, 5 or more  
4. When your doctor first prescribed these pills to you, how was the decision to take them made?
My doctor and I talked about it, and I made the decision
My doctor and I talked about it, and s/he made the decision 
My doctor and I talked about it, and we made the decision together 
My doctor and I didn’t really talk about it—they were just prescribed to me
5.  Did you ever cut back or stop taking your hormonal therapy pills because these pills made you feel bad?      
Yes 
No
6.  Have you forgoen to take your hormonal therapy pills when you were away from home?  
Yes
No
7. For you, scking to your hormonal therapy treatment plan is…
Very hard      
Somewhat hard    
Not hard at all
8. Would you say you have trouble remembering to take your hormonal therapy pills…
Oen  
Somemes      
Praccally Never
9. How oen do you miss your pills because… Oen Somemes Praccally Never
The pills are too expensive    
You forget to take them
The side effects of the pills are too hard to deal with
You don’t get around to filling the prescripon
Taking medicaon for a long me is not healthy               
10. Think about the whole process of taking hormone therapy pills- from filling the prescripon to taking the pills every 
day and pung up with the side effects from them. Do you think…
The good outweighs the bad       
The good and bad are equal   
The bad outweighs the good
11. Suppose you took all your hormone therapy pills as prescribed. What do you think the chances would be that your 
cancer would ever come back?
Very Low    
Low    
Moderate     
High   
Very High
12. Suppose you stopped taking these pills as prescribed. What do you think would happen to your chances of your breast 
cancer coming back?
My chance would go up a lot    
My chance would go up a lile   
My chances would really not change
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by race-specific relationships (eg, the relationship between age
and underuse is different for black vs white women) (45).
Missingness was 5% or less for all variables. Multiple
imputation was performed for missing variables using
SAS Studio (SAS Institute, Cary, NC) to create, analyze, and com-
bine 50 imputed datasets as described by Rubin (46,47). Results
are presented as estimated adjusted odds ratios (ORs) with 95%
confidence intervals (CI) and P values. A statistical significance
level of 5% was used for all analyses. All statistical tests were
two-sided.
Results
Overall, 1280 women reported being prescribed ET and were in-
cluded in our sample; of these, 43.2% self-identified as black,
and mean age at diagnosis was 53 years (Table 1). Overall, black
women more often presented with advanced stage disease,
greater financial vulnerability, lower education, and public in-
surance or uninsured status (Supplementary Table 1, available
online). For black women, 23.7% reported underuse of ET, com-
pared to 15.9% of white women (P < .001) (Table 1). Compared
with white women, black women more often reported non-
adherence (13.7% vs 5.2%, P < .001) but not discontinuation
(10.0% vs 10.7%, P¼ .65). Younger women were more often
underusing ET (P¼ .003), as were those women insured by
Medicaid (P < .001) and those making less than $50 000/y
(P¼ .03). Additionally, women who did not describe their deci-
sion to start ET as a shared decision-making process with their
provider were more often underusing ET (P< .001) (Table 1).
Women prescribed tamoxifen were more often underusing ET
(P< .001), as were those who changed ET type one or more times
(P¼ .008).
A statistically significantly higher proportion of black
women reported the following: forgetting to take ET when trav-
eling away from home (26.2% vs 19.5%, P < .001); sticking to
their ET treatment plan was hard or very hard (27.5% vs 14.0%,
P< .001); trouble remembering to take their ET pills (27.2%
vs 13.2%, P< .001); missing pills due to cost (17.1% vs 6.7%,
P< .001); and severe side effects that led to skipping ET pills
(25.0% vs 16.3%, P< .001) (Table 2). Black women also reported
less often that the “good of taking ET outweighed the bad”
(72.1% vs 79.8%, P< .001) (Table 2). Black women more often
reported that they believed their risk of breast cancer recurrence
was very low if medication was completed but were also twice
as likely to say that their recurrence risk would not change if
they stopped taking ET (Figure 2). Differences in perceived risk
of recurrence by race were not explained by stage at diagnosis
in bivariable analyses (results not shown).
Compared with white women, black women more often
reported hot flashes (57.5% vs 42.5%), night sweats (42.5%
vs 27.7%), breast sensitivity (24.3% vs 15.9%), and joint pain
(46.2% vs 36.3%), as well as almost all other ET-related symp-
toms in the past 7 days (all P< .001) (Figure 3). However, black
women were less likely to report some sexual side effects in-
cluding vaginal dryness (18.7% vs 24.1%, P¼ .02) and painful sex
(11.5% vs 18.9% P¼ .001) compared with white women.
In multivariable models (Table 3), black race was statistically
significantly associated with overall underuse in a model
adjusting only for clinical characteristics and patient percep-
tions of decision making and recurrence risk (adjusted OR ¼
1.44, 95% CI ¼ 1.05 to 1.99), but the association was no longer
statistically significant once socioeconomic variables were
added to the model. In multivariable models predicting
nonadherence specifically, black race was a statistically signifi-
cant predictor after clinical adjustment (adjusted OR ¼ 2.72, 95%
CI ¼ 1.75 to 4.24), and remained statistically significant after fur-
ther adjustment for socioeconomic factors (adjusted OR ¼ 2.44,
95% CI ¼ 1.50 to 3.97). Black race was not statistically signifi-
cantly associated with discontinuation.
The strongest predictor of overall ET underuse, non-
adherence, and discontinuation in fully adjusted models was
believing that recurrence risk does not change if ET is not taken
as prescribed (adjusted OR for underuse ¼ 8.35, 95% CI ¼ 5.34 to
13.1; adjusted OR for nonadherence ¼ 4.07, 95% CI ¼ 2.28 to 7.26;
adjusted OR for discontinuation ¼ 17.63, 95% CI ¼ 9.28 to 33.49)
(Table 3).
Other statistically significant predictors of ET nonadherence
in fully adjusted models included older age and baseline recur-
rence risk perception (P< .05) (Table 3). Statistically significant
predictors of ET discontinuation in fully adjusted models in-
cluded: taking tamoxifen vs aromatase inhibitors (adjusted OR
¼ 1.66, 95% CI ¼ 1.00 to 2.73); reporting a patient-led (adjusted
OR ¼ 3.44, 95% CI ¼ 2.07 to 5.75) or passive (adjusted OR ¼ 2.59,
95% CI ¼ 1.17 to 5.72), rather than shared, decision-making pro-
cess to begin ET; perceiving that recurrence risk increased only
a little if ET was discontinued (adjusted OR ¼ 3.71, 95% CI ¼ 2.05
to 6.74); and having Medicaid insurance relative to private insur-
ance (adjusted OR ¼ 2.27, 95% CI ¼ 1.06 to 2.88).
Finally, relaxing the assumption that covariates behave
identically for black and white women, we estimated race-
stratified models, which suggested racial relationships in terms
of the magnitude and statistical significance for several key pre-
dictors of underuse (Supplementary Table 2, available online)
To compare the relative importance of these coefficient differ-
ences vs differences in underlying cohort characteristics, we
conducted Oaxaca-Blinder decomposition, comparing expected
ET usage for black and white samples with matched character-
istics. We find that characteristic differences between black and
white patients could not fully explain the disparity in ET use.
Characteristic differences account for only 38.6% (95% CI ¼
18.6% to 59.0%) of the racial difference, with the majority of this
variation explained by differences in recurrence risk perception
if pills are discontinued (Table 4). The remainder of the varia-
tion in ET underuse was attributable to differences in model
coefficients and intercepts by race.
Discussion
In a large, racially enriched prospective cohort, we found that
black women with HRþ breast cancer were statistically signifi-
cantly more likely to be nonadherent to ET, but not more likely
to discontinue, and we identified major modifiable predictors of
nonadherence, including differential risk perceptions and a lack
of shared treatment decision making. Our study provides excep-
tional detail on reasons for nonadherence and differences in
the ET experience by race, including risk perception, shared
decision making, and side effect burden. In general, the burden
of self-reported ET-related side effects was worse among black
women, but side effect burden was not correlated with ET ad-
herence. This latter finding may reflect timing of side effect
questions (past 7 days), development of coping strategies, or the
larger impact of psychological rather than physiological factors.
Given the scarcity of literature on ET experiences by race, it
is difficult to compare our results with previous studies.
However, patient-level factors previously associated with ET
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effects, comorbidities, and medication cost (28,48–53). Women
have reported confusion about the hormonal nature of
tamoxifen and distress related to ET side effects such as hot
flashes, weight gain, and loss of fertility (54). We add to this lit-
erature by identifying several adherence barriers that are differ-
ential by race. Notably, racial differences in risk perception
appear to be driving a substantial portion of the increased non-
adherence among black women.
Existing ET interventions have focused on the provision of
educational materials with little benefit (55). Our results suggest
that multifaceted interventions may better address the numer-
ous barriers to improving ET-related risk perception, shared de-
cision making, and medication-taking habits, as opposed to
simply attending to burdensome side effects. To ensure equity,
interventions should consider racial differences in the ET expe-
rience. For example, we find that white women report more sex-
ual side effects, but black women experience numerous other
side effects more often; supportive side effect management can
likely be improved. It may also be important to address cost bar-
riers and concerns about medication use—both more common
among black women. Motivational interviewing counseling is
one example of a multifaceted behavioral intervention success-
ful in improving medication adherence in non-ET contexts
among diverse patients (56,57). Motivational interviewing is in-
herently patient directed and can enable patients to assess
treatment and health goals, identify barriers and facilitators to
healthy behavior, solve problems, and improve self-efficacy
(58,59).
Our study has several limitations. First, our sample is drawn
from Black and White women diagnosed in North Carolina,
which may limit generalizability to women of other races and
ethnicities as well as those in other states. However, CBCS rep-
resents an intentionally sampled cohort of women with breast
cancer in a large, racially and socioeconomically diverse state
with substantial racial disparities in cancer outcomes. Second,
although our questionnaire included previously validated
instruments (35–37), it has not yet been compared to alternative
adherence measures such as electronic pill counters or phar-
macy refill data. Finally, although the cohort was followed pro-
spectively, ET questions were only asked at one time point. This
creates temporal challenges in interpreting risk perceptions and
side effects causally, as women’s responses may be influenced
by their current medication-taking behaviors. Future work
should seek to examine ET-related perceptions and behaviors
with more frequent data collection to capture temporal
granularity.
Strengths of our study include the oversampling of black
women and women younger than age 50 years, the use of rapid
case ascertainment to recruit patients near the time of diagno-
sis, and the longitudinal engagement of patients. We also used
patient-reported instruments to measure medication behaviors
and side effects. Notably, there is no “gold standard” for mea-
suring medication adherence. However, collecting patient-
reported data on medication use enables a deeper understand-
ing of patient experiences (as opposed to using claims or clinical






Total (n ¼ 1280) 727 (56.8) 553 (43.2) —
ET usage behaviors
Nonadherent 38 (5.2) 76 (13.7) <.001
Discontinued 78 (10.7) 55 (10.0) .65
Underuse† 116 (15.9 131 (23.7) <.001
Forgets ET when traveling
Yes 113 (19.5) 139 (26.2) <.001
Difficulty sticking to treatment plan
Hard/very hard 96 (14.0) 145 (27.5) <.001
Trouble remembering to take pills
Often 13 (1.9) 18 (3.4) <.001
Sometimes 77 (11.3) 136 (23.8)
Missed pills due to cost
Often 18 (2.6) 44 (8.5) <.001
Sometimes 28 (4.1) 45 (8.6)
Missed pills due to not refilling promptly
Often 10 (1.5) 22 (4.2) <.001
Sometimes 34 (5.0) 47 (9.1)
Skipped pills due to severity of side effects <.001
Often 56 (8.1) 43 (8.2)
Sometimes 57 (8.2) 88 (16.8)
Skipped pills due to concerns about long-term medication use <.001
Often 37 (5.4) 48 (9.3)
Sometimes 63 (9.2) 107 (20.7)
Opinion of ET overall <.001
Good outweighs bad 561 (79.8) 379 (72.1)
Neutral 85 (12.1) 109 (20.7)
Bad outweighs good 57 (8.1) 38 (7.2)
*P values were calculated using a two-sided v2 test comparing black vs white women.
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Figure 3. Percent of women reporting experiencing symptoms either “quite a bit” or “very much” in the past 7 days, by race. The analysis included 1267 women. P val-
ues were calculated using a two-sided v2 test comparing black vs white women. The bars represent 95% confidence intervals.
A
B
Figure 2. Perceived risk of breast cancer recurrence, by race. A) Participants’ perceived risk of cancer recurrence if endocrine therapy was completed as prescribed, by
race (n¼1220). B) Participants’ perceived change in risk of cancer recurrence if endocrine therapy pills were not completed as prescribed, by race (n¼1212). P values
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data), and therefore plays an important role in adherence
research.
Data from our minority-enriched sample suggest that patient-
reported reasons for ET underuse, such as lack of belief in treat-
ment efficacy, poor awareness of benefits, and poor communication
with providers, are more prevalent in black women. Each of these rep-
resents a potentially modifiable barrier where opportunities exist to
intervene to improve ET use. Our work provides much-needed, timely
information to fill large gaps in the understanding of ET behaviors
among minority women with breast cancer. Recognition of racial dif-
ferences and attention to the needs of minority women during inter-
vention development will help to ensure they are not left behind in
our efforts to improve ET use.
Effective behavioral interventions to improve ET continuation
and adherence that are relevant, feasible, acceptable, and scal-
able within racially diverse populations are needed. Motivational
interviewing counseling is one such intervention that has been
successful in improving medication adherence in other settings
and may be suitable in this context (40,56,57). In turn, optimizing
the delivery of ET will eventually lead to less breast cancer recur-
rence and greater improvements in mortality, with potentially














































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. Racial decomposition* of endocrine therapy underuse†: ex-







ET type 0.002 (0.006, 0.001) 3.1
Stage 0.006 (0.014, 0.001) 8.0
Received Herceptin 0.002 (0.006, 0.002) 2.6
Received chemotherapy 0.001 (0.004, 0.006) 1.1
Received fadiation 0.004 (0.002, 0.009) 4.6
Mastectomy 0.001 (0.002, 0.001) 0.8
Age at diagnosis 0.005 (0.001, 0.011) 6.8
ET decision making 0.000 (0.005, 0.005) 0.1
Perception of recurrence
risk if ET completed
0.004 (0.008, 0.001) 5.8
Perception of risk if ET
discontinued
0.026 (0.012, 0.040) 33.4
Insurance type 0.018 (0.006, 0.042) 23.1
Education level 0.004 (0.005, 0.013) 5.1
Endocrine symptom
subscale
0.000 (0.006, 0.007) 0.5
Marital status 0.000 (0.016, 0.016) 0.2
Annual household
income
0.012 (0.041, 0.017) 15.4
Total explained 0.030 (0.014, 0.045)
Total gap 0.077 (—)
Percent Explained
(95% CI)
— 38.6 (18.6 to 59.0)
*Oaxaca-Blinder decomposition. CI ¼ confidence interval; ET ¼ endocrine
therapy.
†Underuse is defined as self-reporting either nonadherence (not taking medica-
tion as prescribed) or discontinuation (stopping medication altogether) at
2 years postdiagnosis.
‡Decomposition was performed using the Fairlie method for nonlinear decom-
position (45). This method estimates outcomes using a combination of average
characteristics from white participants and regression coefficients for black par-
ticipants using the race-stratified model. Percentages describe the estimated re-
duction in adherence differences if black participants were given identical
distributions of each characteristic to those of white participants; the total
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